NASDAQ$JANX
Janux Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Janux Therapeutics Inc reported no collaboration revenue and a net loss of $33.9 million for Q2 2025.
The company recorded zero collaboration revenue in the quarter as its research activities under the Merck agreement were completed in 2024. Operating expenses increased significantly to $45.1 million driven by higher R&D spend on preclinical and clinical programs. The net loss widened to $33.9 million while the company maintained a strong liquidity position with over $996 million in cash, cash equivalents and short-term investments.
- Collaboration revenue was $0 for the three months ended June 30, 2025, compared to $8.9 million in the prior year period.
- Research and development expenses rose to $34.7 million, up from $14.9 million year-over-year, reflecting expanded pipeline activities.
- Net loss per share was $(0.55) on a weighted average of 61.9 million shares outstanding.
- Cash, cash equivalents and short-term investments totaled $996.0 million at quarter end, providing substantial runway.
Headline financials
Revenue & EPS history
Janux · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+0.6%
Avg return
Earnings day
-1.5%
Avg return
5 days after
-5.5%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+14.6%
Q3 2022
Best reaction
-11.0%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -0.6% | -1.4% | -8.8% | |
| Q4 2025 | -1.4% | +4.0% | -4.5% | |
| Q3 2025 | +3.9% | +4.8% | -40.1% | |
| Q1 2025 | -0.8% | +3.8% | -2.8% | |
| Q4 2024 | +2.7% | -1.6% | -9.1% | |
| Q3 2024 | -1.9% | -2.9% | +17.6% | |
| Q2 2024 | -1.1% | -0.8% | +11.8% | |
| Q1 2024 | -11.0% | -21.3% | -31.5% | |
| Q4 2023 | -1.6% | -1.7% | -13.5% | |
| Q3 2023 | +5.9% | -3.4% | +50.7% | |
| Q2 2023 | +5.1% | +4.3% | -11.6% | |
| Q1 2023 | +1.1% | -7.0% | -3.5% | |
| Q4 2022 | -2.5% | -4.7% | -4.9% | |
| Q3 2022 | +14.6% | +5.3% | -9.8% | |
| Q2 2022 | +1.0% | -4.9% | -3.2% | |
| Q1 2022 | +6.1% | +13.7% | +10.0% | |
| Q4 2021 | -6.0% | -3.5% | -17.1% | |
| Q3 2021 | -1.6% | -7.4% | -23.9% | |
| Q2 2021 | -1.0% | -3.8% | -9.9% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro